Oral Anticoagulation in Patients with Chronic Liver Disease

Oral Anticoagulation in Patients with Chronic Liver Disease

The administration of an anticoagulant in patients with liver disease (nonalcoholic steatohepatitis—NASH, nonalcoholic fatty liver disease—NAFLD, chronic hepatitis, or cirrhosis) who have an indication (atrial fibrillation, venous thrombosis, or pulmonary embolism) is challenging because there is an...

Full description

Bibliographic Details
Main Authors:	Raluca S. Costache, Andreea S. Dragomirică, Bogdan E. Gheorghe, Vasile D. Balaban, Silviu M. Stanciu, Mariana Jinga, Daniel O. Costache
Format:	Article
Language:	English
Published:	MDPI AG 2023-02-01
Series:	Medicina
Subjects:	liver disease VKAs DOACs atrial fibrillation venous thrombosis
Online Access:	https://www.mdpi.com/1648-9144/59/2/346

Similar Items

Management of Patients Treated with Direct Oral Anticoagulants in Clinical Practice and Challenging Scenarios
by: Fabiana Lucà, et al.
Published: (2023-09-01)

Outcome of antithrombotic therapy in cancer patients with catheter-related thrombosis: a systematic review
by: Qinan Yin, et al.
Published: (2023-12-01)

Demographic, clinical, and functional determinants of antithrombotic treatment in patients with nonvalvular atrial fibrillation
by: Jose María Mostaza, et al.
Published: (2021-08-01)

Cognitive impairment in patients with atrial fibrillation: What is the importance of anticoagulant therapy?
by: Giovanni Capobianco
Published: (2018-06-01)

Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients
by: Song AB, et al.
Published: (2019-06-01)

Physicians’ Perceptions of Their Patients’ Attitude and Knowledge of Long-Term Oral Anticoagulant Therapy in Bulgaria
by: Nikolay Runev, et al.
Published: (2019-06-01)

Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients
by: Alessandra M. Campos-Staffico, et al.
Published: (2022-11-01)

Changing or Retaining Direct Oral Anticoagulant After Ischemic Stroke Despite Direct Oral Anticoagulant Treatment
by: Shin‐Yi Lin, et al.
Published: (2024-02-01)

Nine‐year trend of oral anticoagulant use in patients with embolic stroke due to nonvalvular atrial fibrillation
by: Chisa Asahina, et al.
Published: (2020-10-01)

Five Years of Direct Oral Anticoagulants Use in Italy: Adverse Drug Reactions from the Italian National Pharmacovigilance Network
by: Carlo Lavalle, et al.
Published: (2022-06-01)

An update on applications and limitations of direct oral anticoagulants
by: Sharon Wei, et al.
Published: (2023-04-01)

A Systematic Review of the Efficacy and Safety of Direct Oral Anticoagulants in Atrial Fibrillation Patients with Diabetes Using a Risk Index
by: Domenico Acanfora, et al.
Published: (2021-06-01)

Comparing Efficacy and Safety Between Patients With Atrial Fibrillation Taking Direct Oral Anticoagulants or Warfarin After Direct Oral Anticoagulant Failure
by: Meng‐Tsang Hsieh, et al.
Published: (2023-12-01)

Safety and efficacy of direct oral anticoagulants in stroke prevention in patients with atrial fibrillation complicated with anemia and/or thrombocytopenia: a retrospective cohort study
by: Wenlin Xu, et al.
Published: (2023-11-01)

Use of direct oral anticoagulants in hematologic malignancies
by: Ilona Leviatan, et al.
Published: (2023-12-01)

Direct oral anticoagulants for the treatment of cerebral venous thrombosis – a protocol of an international phase IV study
by: Anita van de Munckhof, et al.
Published: (2023-09-01)

Patients’ and clinicians’ perceptions of oral anticoagulants in atrial fibrillation: a systematic narrative review and meta-analysis
by: Yeyenta Mina Osasu, et al.
Published: (2021-12-01)

Anticoagulant activity of apixaban can be estimated by multiple regression analysis
by: Naoko Unami, et al.
Published: (2020-12-01)

Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran
by: Maha Al-Ghafry, et al.
Published: (2022-10-01)

Effect of Some Risk Factors on Over-Anticoagulation Disorders and Bleeding in Patients Receiving Anticoagulant Therapy with Overdosage of Vitamin K Antagonist
by: Dung Chu S, et al.
Published: (2023-10-01)

Retrospective Comparison of Patients ≥ 80 Years With Atrial Fibrillation Prescribed Either an FDA-Approved Reduced or Full Dose Direct-Acting Oral Anticoagulant
by: Roy Taoutel, et al.
Published: (2022-12-01)

New Oral Anticoagulants vs. Vitamin K Antagonists Among Patients With Cardiac Amyloidosis: Prognostic Impact
by: Eve Cariou, et al.
Published: (2021-11-01)

Inappropriate dosing of direct oral anticoagulants: findings from a clinical vignette study and physician survey
by: Ahmet Fuat, et al.
Published: (2023-12-01)

Management of Direct Oral Anticoagulants in Patients with Atrial Fibrillation Undergoing Cardioversion
by: Giuseppe Coppola, et al.
Published: (2019-09-01)

Inappropriate Underdosing of Direct Oral Anticoagulants in Atrial Fibrillation Patients: Results from the START2-AF Registry
by: Daniela Poli, et al.
Published: (2024-03-01)

Use and Prescription of Direct Oral Anticoagulants in Older and Frail Patients with Atrial Fibrillation: A Multidisciplinary Consensus Document
by: Marco Proietti, et al.
Published: (2022-03-01)

Clot time ratio (CTR) and relation to treatment outcome in patients with atrial fibrillation treated with Rivaroxaban
by: Liselotte Onelöv, et al.
Published: (2024-03-01)

Editorial: Anticoagulation in cardiovascular diseases: evolving role, unmet needs, and grey areas
by: Antonino Tuttolomondo, et al.
Published: (2023-10-01)

Impact of amiodarone on plasma concentration of direct oral anticoagulant in patients with atrial fibrillation
by: Shin-Yi Lin, et al.
Published: (2023-08-01)

Risk Profiles of New Users of Oral Anticoagulants Between 2011 and 2019 in Germany
by: Voss A, et al.
Published: (2023-07-01)

Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO)
by: David Mocini, et al.
Published: (2021-09-01)

Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm
by: Marek Z. Wojtukiewicz, et al.
Published: (2020-05-01)

Estimated Thresholds of Minimum Necessary Adherence for Effective Treatment with Direct Oral Anticoagulants – A Retrospective Cohort Study in Health Insurance Claims Data
by: Wirbka L, et al.
Published: (2021-09-01)

Modeling patients’ time, travel, and monitoring costs in anticoagulation management: societal savings achievable with the shift from warfarin to direct oral anticoagulants
by: Aapeli Leminen, et al.
Published: (2019-11-01)

Efficacy and Safety of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and High Thromboembolic Risk. A Systematic Review
by: Domenico Acanfora, et al.
Published: (2019-09-01)

Tailored Direct Oral Anticoagulation in Patients with Atrial Fibrillation: The Future of Oral Anticoagulation?
by: Matej Samoš, et al.
Published: (2022-10-01)

Direct Oral Anticoagulants in Patients on Chronic Dialysis and Concomitant Atrial Fibrillation: A Common Clinical Impasse
by: Nikolaos Ktenopoulos, et al.
Published: (2022-07-01)

Incidence of left atrial appendage thrombus despite 3 weeks of anticoagulation and the need for precardioversion echocardiography
by: Marc Erickson, et al.
Published: (2022-09-01)

How to manage anticoagulation for cancer-associated thrombosis and atrial fibrillation in cancer
by: Antonella Tufano, et al.
Published: (2024-06-01)

A Tailored Antithrombotic Approach for Patients with Atrial Fibrillation Presenting with Acute Coronary Syndrome and/or Undergoing PCI: A Case Series
by: Simona Giubilato, et al.
Published: (2022-07-01)